Charles River Laboratories International, Inc. revised financial guidance for 2024. For the period, the company expects revenue growth to be 1.0% to 4.0% compared to previous guidance of 1.0% to 4.0%, organic revenue growth of 0.0% to 3.0% compared to previous guidance of 0.0% to 3.0%, GAAP EPS estimate $7.60 to $8.10 compared to previous guidance of $7.90-$8.40.
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
210.7 USD | -0.43% |
|
+0.97% | -10.99% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.99% | 10.9B | |
+35.41% | 51.12B | |
-6.49% | 39.4B | |
+36.08% | 38.48B | |
+12.22% | 26.36B | |
-12.11% | 26.22B | |
+11.11% | 20.96B | |
+43.20% | 14.02B | |
+31.67% | 12.49B | |
-4.22% | 11.61B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International, Inc. Revises Financial Guidance for 2024